X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
42
PharmaCompass offers a list of Pioglitazone Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Pioglitazone Hydrochloride manufacturer or Pioglitazone Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Pioglitazone Hydrochloride manufacturer or Pioglitazone Hydrochloride supplier.
PharmaCompass also assists you with knowing the Pioglitazone Hydrochloride API Price utilized in the formulation of products. Pioglitazone Hydrochloride API Price is not always fixed or binding as the Pioglitazone Hydrochloride Price is obtained through a variety of data sources. The Pioglitazone Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A AM20061770 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of AM20061770, including repackagers and relabelers. The FDA regulates AM20061770 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. AM20061770 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of AM20061770 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A AM20061770 supplier is an individual or a company that provides AM20061770 active pharmaceutical ingredient (API) or AM20061770 finished formulations upon request. The AM20061770 suppliers may include AM20061770 API manufacturers, exporters, distributors and traders.
click here to find a list of AM20061770 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A AM20061770 DMF (Drug Master File) is a document detailing the whole manufacturing process of AM20061770 active pharmaceutical ingredient (API) in detail. Different forms of AM20061770 DMFs exist exist since differing nations have different regulations, such as AM20061770 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A AM20061770 DMF submitted to regulatory agencies in the US is known as a USDMF. AM20061770 USDMF includes data on AM20061770's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The AM20061770 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of AM20061770 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The AM20061770 Drug Master File in Japan (AM20061770 JDMF) empowers AM20061770 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the AM20061770 JDMF during the approval evaluation for pharmaceutical products. At the time of AM20061770 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of AM20061770 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a AM20061770 Drug Master File in Korea (AM20061770 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of AM20061770. The MFDS reviews the AM20061770 KDMF as part of the drug registration process and uses the information provided in the AM20061770 KDMF to evaluate the safety and efficacy of the drug.
After submitting a AM20061770 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their AM20061770 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of AM20061770 suppliers with KDMF on PharmaCompass.
A AM20061770 CEP of the European Pharmacopoeia monograph is often referred to as a AM20061770 Certificate of Suitability (COS). The purpose of a AM20061770 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of AM20061770 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of AM20061770 to their clients by showing that a AM20061770 CEP has been issued for it. The manufacturer submits a AM20061770 CEP (COS) as part of the market authorization procedure, and it takes on the role of a AM20061770 CEP holder for the record. Additionally, the data presented in the AM20061770 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the AM20061770 DMF.
A AM20061770 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. AM20061770 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of AM20061770 suppliers with CEP (COS) on PharmaCompass.
A AM20061770 written confirmation (AM20061770 WC) is an official document issued by a regulatory agency to a AM20061770 manufacturer, verifying that the manufacturing facility of a AM20061770 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting AM20061770 APIs or AM20061770 finished pharmaceutical products to another nation, regulatory agencies frequently require a AM20061770 WC (written confirmation) as part of the regulatory process.
click here to find a list of AM20061770 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing AM20061770 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for AM20061770 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture AM20061770 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain AM20061770 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a AM20061770 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of AM20061770 suppliers with NDC on PharmaCompass.
AM20061770 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of AM20061770 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right AM20061770 GMP manufacturer or AM20061770 GMP API supplier for your needs.
A AM20061770 CoA (Certificate of Analysis) is a formal document that attests to AM20061770's compliance with AM20061770 specifications and serves as a tool for batch-level quality control.
AM20061770 CoA mostly includes findings from lab analyses of a specific batch. For each AM20061770 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
AM20061770 may be tested according to a variety of international standards, such as European Pharmacopoeia (AM20061770 EP), AM20061770 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (AM20061770 USP).
Market Place
